Predictive Potential of PD-L1, TYMS, and DCC Expressions in Treatment Outcome of Colorectal Carcinoma

Onwe, Ebenyi Emeka; Ghani, Fauzah Abd; Abdullah, Maha; Osman, Malina; Zin, Reena Rahayu Md; Vivian, Arimokwu Nimbi; Mohtarrudin, Norhafizah

doi:10.1007/5584_2020_521

Cited by 2 publications

(1 citation statement)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To assess the differences in the tumor immune microenvironment between sexes, tumor expression of PD-L1 in tumors from females and males investigated. Six studies compared PD-L1 expression in male and female CRC patients 20 – 25 , while one study reported only on MSI-H CRC patients 26 . No significant difference could be identified between sexes, with male patients having only a slightly lower probability to have PD-L1 positive tumors (odds ratio=0.95, 95% CI=0.80–1.14 fixed+random model) (Figs 2 a, 3 b).…”

Section: Resultsmentioning

confidence: 99%

IMMUNOREACT 5: female patients with rectal cancer have better immune editing mechanisms than male patients – a cohort study

Spolverato

Fassan

Capelli

et al. 2023

International Journal of Surgery

View full text Add to dashboard Cite

Background: Studies evaluating sex differences in colorectal cancer (CRC) tumor microenvironment are limited, and no previous study has focused on rectal cancer patients’ constitutive immune surveillance mechanisms. The authors aimed to assess gender-related differences in the immune microenvironment of rectal cancer patients. Methods: A systematic review and meta-analysis were conducted up to 31 May 2021, including studies focusing on gender-related differences in the CRC tumor microenvironment. Data on the mutational profile of rectal cancer were extracted from the Cancer Genome Atlas (TCGA). A subanalysis of the two IMMUNOREACT trials (NCT04915326 and NCT04917263) was performed, aiming to detect gender-related differences in the immune microenvironment of the healthy mucosa in patients with early (IMMUNOREACT 1 cohort) and locally advanced rectal cancer following neoadjuvant therapy (IMMUNOREACT 2 cohort). In the retrospective IMMUNOREACT 1 cohort (therapy naive), the authors enrolled 442 patients (177 female and 265 male), while in the retrospective IMMUNOREACT 2 cohort (patients who had neoadjuvant therapy), we enrolled 264 patients (80 female and 184 male). In the prospective IMMUNOREACT 1 cohort (therapy naive), the authors enrolled 72 patients (26 female and 46 male), while in the prospective IMMUNOREACT 2 cohort (patients who had neoadjuvant therapy), the authors enrolled 105 patients (42 female and 63 male). Results: Seven studies reported PD-L1 expression in the CRC microenvironment, but no significant difference could be identified between the sexes. In the TGCA series, mutations of SYNE1 and RYR2 were significantly more frequent in male patients with rectal cancer. In the IMMUNOREACT 1 cohort, male patients had a higher expression of epithelial cells expressing HLA class I, while female patients had a higher number of activated CD4+Th1 cells. Female patients in the IMMUNOREACT 2 cohort showed a higher infiltration of epithelial cells expressing CD86 and activated cytotoxic T cells (P=0.01). Conclusions: Male patients have more frequent oncogene mutations associated with a lower expression of T-cell activation genes. In the healthy mucosa of female patients, more Th1 cells and cytotoxic T cells suggest a potentially better immune response to the tumor. Sex should be considered when defining the treatment strategy for rectal cancer patients or designing prognostic scores.

show abstract

Section: Resultsmentioning

confidence: 99%

IMMUNOREACT 5: female patients with rectal cancer have better immune editing mechanisms than male patients – a cohort study

Spolverato

Fassan

Capelli

et al. 2023

International Journal of Surgery

View full text Add to dashboard Cite

show abstract

Genetic analysis of colorectal carcinoma using high throughput single nucleotide polymorphism genotyping technique within the population of Jammu and Kashmir

et al. 2021

View full text Add to dashboard Cite

Background SNP genotyping has become increasingly more common place to understand the genetic basis of complex diseases like cancer. SNP-genotyping through massARRAY is a cost-effective method to quantitatively analyse the variation of gene expression in multiple samples, making it a potential tool to identify the underlying causes of colorectal carcinogenesis. Methods In the present study, SNP genotyping was carried out using Agena mass ARRAY, which is a costeffective, robust, and sensitive method to analyse multiple SNPs simultaneously. We analysed 7 genes in 492 samples (100 cases and 392 controls) associated with CRC within the population of Jammu and Kashmir. These SNPs were selected based on their association with multiple cancers in literature.Results This is the rst study to explore these SNPs with colorectal cancer within the J&K population.7SNPs with a call rate of 90% were selected for the study. Out of these, one SNP i.e. rs2229080 of DCC was found to be signi cantly associated with the current study and 6 were non-signi cantly associated with CRC within the studied population. The allelic OR observed for the variant rs2229080 of DCC was 1.5 (1.1-2.3 at 95% CI), p value = 0.02.Conclusion This is the rst study to nd the relation of Genetic variants with the colorectal cancer within the studied population using high throughput mass ARRAY technology. It is further anticipated that the variants should be evaluated in other population groups that may aid in understanding the genetic complexity and bridge the missing heritability.

show abstract

Predictive Potential of PD-L1, TYMS, and DCC Expressions in Treatment Outcome of Colorectal Carcinoma

Cited by 2 publications

References 48 publications

IMMUNOREACT 5: female patients with rectal cancer have better immune editing mechanisms than male patients – a cohort study

IMMUNOREACT 5: female patients with rectal cancer have better immune editing mechanisms than male patients – a cohort study

Genetic analysis of colorectal carcinoma using high throughput single nucleotide polymorphism genotyping technique within the population of Jammu and Kashmir

Contact Info

Product

Resources

About